The Efficacy and Safety of using Nebulized Antibiotics in Treatment of Ventilator-Associated Pneumonia | ||||
Benha Journal of Applied Sciences | ||||
Article 16, Volume 4, Issue 1, March 2019, Page 91-95 PDF (523.2 K) | ||||
Document Type: Original Research Papers | ||||
DOI: 10.21608/bjas.2019.187098 | ||||
View on SCiNiTO | ||||
Authors | ||||
O.S. Arafa1; T.S. Essawy2; B.M. Aglan3; E.A. Attaya4 | ||||
1Cardiology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
2Chest Dept, Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
3Cardio thoracic Dept, Faculty of Medicine, Benha Univ., Benha, Egypt | ||||
4Critical Care Dept, Faculty of Medicine, Benha Univ, Benha, Egypt | ||||
Abstract | ||||
Development of ventilator- associated pneumonia [VAP] is associated with high morbidity and mortality rates. VAP mortality ranges between 5.8% and 27% [1]. Routine administration of intravenous antibiotics does not reach a bactericidal concentration in lung tissues. intravenous antibiotics are mainly detected in respiratory segments of lungs, but not in sputum [2].This study was conducted on 60 patients who were admitted to critical care department at Benha University Hospital and diagnosed with Ventilator Associated Pneumonia [VAP]. patients were divided into two groups: Group A included 30 patients have received only systemic antibiotics and Group B included 30 patients have received systemic and nebulized antibiotics. In this study the clearance of organism, resistance, superinfection and combined [resistance and super infection] were significantly different in group A vs.B .There was significant decrease regarding creatinine level in group B vs. A .There were significant reduction in duration of MV and length of ICU stay in group B vs. A.Nebulized Amikacin plus ceftazidime are effective in the treatment of VAP. | ||||
Statistics Article View: 73 PDF Download: 247 |
||||